NCT02636244Phase 2Status unknown
Safety and Efficacy Study of SHAPE Gel in Alopecia Areata
A Multi-Center, Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of SHAPE Gel, a Histone Deacetylase Inhibitor, in Patients With Alopecia Areata
In the register
The register attaches this trial to Remetinostat (SHP-141, SHAPE gel) (TetraLogic Pharmaceuticals), currently at “Discontinued” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Status unknown
- Declared phase
- Phase 2
- Sponsor
- TetraLogic Pharmaceuticals
- Participants (registry)
- 40
- Start
- February 2017
- Primary completion
- August 2017
- Study completion
- January 2018
- Last registry update
- October 2016
- Countries
- —
Conditions studied: Alopecia Areata
Interventions: SHAPE Gel, SHP-141
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.